1 / 30

Antiviral therapy

Antiviral therapy. E.McNamara. Challenges. Virus parasitize host cells Target the virus specifically Latency, quiescent phase Is treatment necessary? Efficacy of Rx. Current agents. Exploit viral : host replication Target viral DNA polymerases Accumulate in viral infected cells

colton
Télécharger la présentation

Antiviral therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Antiviral therapy E.McNamara

  2. Challenges • Virus parasitize host cells • Target the virus specifically • Latency, quiescent phase • Is treatment necessary? • Efficacy of Rx.

  3. Current agents • Exploit viral : host replication • Target viral DNA polymerases • Accumulate in viral infected cells • Activated by virus encoded enzymes • Dose related toxicity

  4. Acyclovir • Nucleoside analogue • Inhibits viral DNA polymerase • Stops replicating viral DNA chains • Excreted via renal • Serum half life 2-3 hrs • Good tissue distribution • Activated by HSV-TK to triphosphate form

  5. Acyclovir toxicities • CNS, • Confusion, seizures, coma. • Highest risk • Renal impairment • Old age • Prior mental disability • Potential teratogenicity • Resistance

  6. In-vitro HSV VZV EBV CMV In-vivo HSV VZV Acyclovir, uses

  7. Famciclovir • Nucleotide analogue • Similar spectrum to acyclovir • Similar mode of action • Inactive prodrug of penciclovir • Activated by viral-TK to penciclovir

  8. Famciclovir cont. • Greater bioavailability • Prolonged intracellular half-life • TID dosing

  9. Famciclovir toxicities • No major S/E • Potentially teratogenic • Potential male infertility • Levels increased by probenecid • May increase digoxin levels

  10. Valaciclovir • Valyl ester of acyclovir • P.O. metabolised to acyclovir • Plasma levels equivalent to IV acyclovir • Sustitute for IV acyclovir • Bioavailability dependant on GIT and hepatic function

  11. Valaciclovir • Toxicities similar to acyclovir • TTP in immunocompromised on prolonged Rx.

  12. Penciclovir • Nucleoside analogue • Similar activity to acyclovir • Topical, Herpes labialis.

  13. Herpes infection Rx. • Improved PO bioavailability • Different mode of action-resistance • Improved efficacy • Type, • Primary • Secondary/reactivation • Suppressive Rx. • Vaccines and immunomodulators

  14. Herpes Rx. • HSV • Herpes labialis • Genital herpes • Encephalitis • Immunocompromised • VZV • H.zoster • EBV

  15. Gangciclovir • Competively inhibits viral DNA polymerase • Incoporates into viral DNA, chain terminator • Major agent for CMV • Accumulates in CMV infected cells • Excreted renally • Crosses Blood Brain Barrior

  16. Gangciclovir, toxicity • Haematologic/bone marrow • Neutropaenia • Thrombocytopaenia • Interacts with cytotoxic drugs • Renal impairment • Carcinogenic • Potentiated by probenecid

  17. Foscarnet • Binds viral DNA polymerase and RT. • Active v Herpes viruses • Not curative • Excreted renally • Variable half-life • Impairs biochem. • Monitor u/e, creatinine

  18. Fomivirsen • Active v CMV • Inactivates CMV mRNA • Local, no systemic anti-CMV Rx. • Substitute for CMV retinitis Rx. • Intra-vitreal injections • S/E, intraocular pressure, retinal toxicity

  19. CMV management • Disseminated disease • Gangciclovir/Foscarnet/ • CMV-Iggs, pneumonitis BMT • Prophylaxis/preemptive in Tx. • Gangciclovir/acyclovir/valaciclovir • Retinitis • Formiversin/gangciclovir -local

  20. Amantadine • Inhibits Influ-A uncoating on host cell entry • Early Rx. Within 48hrs of symptoms • Prophylaxis of unimmunised high risk • Combined with vaccine until immunity develops • Renal excretion • Rapid resistance • S/E, CNS- dissyness, seizures

  21. Rimantadine • Structural analogue of amantadine • Fewer CNS S/E

  22. Ribavirin • Synthetic nucleoside • Interferes with viral RNA transcription • Acts on RNA viruses • RSV, HCV • Measles • Lassa fever • Hantaviruses

  23. Ribavirin uses • Ribavirin + alpha-interferon for • Chronic HCV • Monitor Hb + WCC • Aerosol route for RSV, infants • IV for lassa/hanta

  24. Ribavirin toxicities • Potentially teratogenic • C.I. For 6 months pre-pregnancy • Anaemia • Exacerbation of COPD via aerosol

  25. Interferons • Natural glycopeptides • Induced by viruses (dsRNA) • Affect • Antiviral • Antitumour • Immunomodulators • Action, induce cellular enzymes to stop protein synthesis and activate RNA degradation

  26. Interferons, types • Alpha-interferon, B-lymphocytes • Beta-interferon, fibroblasts • Gamma-interferon, T-lymphocytes • Recombinant • Interferon alfacon-1 • Interferon alfacon-2

  27. Interferons, uses • Routes, SC, IM, intralesional • Chronic HCV • Condyloma acuminata-intralesional • Chronic HBV, remission

  28. Interferons, toxicities • Flu-like symptoms • Alopecia • Exac. Psoriasis • Depression • Retinal haemorrhages, rare

  29. Viral hepatitis • HAV, • Supportive • Prophylaxis with HAV IGg • Vaccine • HBV • Interferon-alpha • Lamivudine • Vaccine /HBIG • HCV • Interferon +ribavirin, Tx.

  30. New agents • Oseltramavir – PO • Zanamivir – topical • Neuraminidase inhibitors • Active v Influenza A+B • Sorivudine-VZV+HSV1, 2 step activation • Cidofovir, resistant HSV and CMV

More Related